Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):876-8. doi: 10.1097/00126334-200407010-00016.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / methods
  • Drug Resistance, Viral
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1* / drug effects
  • HIV-1* / isolation & purification
  • Humans
  • Organophosphonates / therapeutic use*
  • RNA, Viral / blood*
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Tenofovir
  • Treatment Outcome
  • Viremia / drug therapy
  • Viremia / virology

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Adenine